Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2637-2652

  Sunder Plassmann, G ^a   Winkelmayer, W C ^a   Fodinger, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arteriosclerosis; Atherosclerosis; Cardiovascular disease; CBS; Folate; Folic acid; MS; MSR; MTHFR; Thrombosis; Total homocysteine; Vitamin B12; Vitamin B1; Vitamin B2; Vitamin B6

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; ALPHA TOCOPHEROL; AMINO ACID; AMINOTRANSFERASE; ASCORBIC ACID; CREATININE; CYANOCOBALAMIN; CYSTATHIONINE; CYSTATHIONINE BETA SYNTHASE; FLAVINE ADENINE NUCLEOTIDE; FOLIC ACID; GLYCINE; HOMOCYSTEINE; INSULIN; LEVOTHYROXINE; METHIONINE; METHIONINE SYNTHASE; METHYLENETETRAHYDROFOLIC ACID; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOREDUCTASE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; RIBOFLAVIN; SERINE; THIAMINE; UNINDEXED DRUG;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MASS SCREENING; MORBIDITY; MORTALITY; PREVALENCE; REVIEW; STROKE; TISSUE INJURY; TISSUE REPAIR; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 0033756697     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2637     Document Type: Review

References (119)

1. Homocysteine and vascular disease
2. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
3. Homocysteine and thrombotic disease
4. Homocysteine and its disulfide derivatives: A suggested consensus terminology
5. Disorders of transsulfuration
6. The folate cycle and disease in man
7. No net renal extraction of homocysteine in fasting humans
8. Homocysteine and methionine metabolism in ESRD: A stable isotope study
9. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism
10. Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men [letter]
11. Inherited disorders of folate transport and metabolism
12. Homocysteine theory of arteriosclerosis
13. Recent insights into the molecular genetics of the homocysteine metabolism
14. Molecular genetics of homocysteine metabolism
15. Molecular biology of 5,10-methylenetetrahydrofolate reductase
16. Polygenic influence on plasma homocysteine: Association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels
17. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
18. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
19. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders
20. 12) increases risk for spina bifida
21. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism
22. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?
23. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
24. Prospective study of coronary heart disease incidence in relation to fasting homocysteine, related genetic polymorphisms and B vitamins
25. Recent data are not in conflict with homocysteine as a cardiovascular risk factor
26. Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas
27. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
28. Effect of MTHFR 677C> T on plasma total homocysteine levels in renal graft recipients
29. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
30. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients
31. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
32. Effect of MTHFR 1298A-> C and MTHFR 677C-> T genotypes on total homocysteine, folate and vitamin B12 plasma concentrations in kidney graft recipients
33. Association of two polymorphisms in MTHFR with total homocysteine plasma levels in dialysis patients
34. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methyleneterahydrofolate reductase genotypes
35. Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid
36. Comparison of intravenous folinic acid with intravenous folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. A randomized, double blinded trial
37. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study
38. Measurement and use of total plasma homocysteine
39. Homocyst(e)ine, diet and cardiovascular diseases. A statement for healthcare professionals from the Nutrition Committee, American Heart Association
40. 12 and folate deficiency: A guide for the primary care physician
41. Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: Differences between the radioassay and microbiological assays
42. Serum methylmalonic acid in uraemia
43. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
44. Relationship between methylmalonic acid and cobalamin in uremia
45. Trends in molecular diagnosis
46. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
47. An alternative view of homocysteine
48. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
49. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
50. Hyperhomocysteinemia and venous thrombosis: A meta-analysis
51. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients
52. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
53. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
54. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
55. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
56. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
57. Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients
58. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
59. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
60. The effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. A prospective study
61. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism
62. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation
63. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines
64. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis
65. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
66. Homocysteine-induced endoplasmatic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells
67. Hyperhomocysteinemia in chronic renal disease
68. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
69. Nutritional status of elderly female nursing home residents; the effect of supplementation with a physiological dose of water-soluble vitamins
70. Vitamin intake: A possible determinant of plasma homocysteine among middle-aged adults
71. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: Results among US men
72. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
73. The effect of folic acid fortification on plasma folate and total homocysteine concentrations
74. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia [letter]
75. 6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
76. Endpoints for homocysteine-lowering trials
77. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins
78. Influence of folic acid on postprandial endothelial dysfunction
79. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia
80. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
81. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
82. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial
83. 5-Methyltetrahydrofolate restores the impaired renal vasodilator response attributed to endothelium derived hyperpolarizing factor in diabetic rats
84. Homocyst(e)ine, vitamins and genetic interactions in vascular disease
85. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial
86. The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations
87. High prevalence of hyperhomocysteinemia in critically ill patients
88. Homocysteine and laminine are not prognostic markers in patients with septic inflammatory response syndrome
89. Reversal of hyperhomocyst(e)inaemia in chronic renal failure - Is folic or folinic acid the answer?
90. 5-Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma
91. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease
92. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients
93. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
94. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease
95. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations
96. Effective correction of hyperhomocyst(e)inemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
97. Lipid peroxidation in hemodialysis: Preventive role of vitamin E and folinic acid
98. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
99. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
100. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
101. Influence of haemodialysis on plasma total homocysteine concentration
102. Randomized trial of high-flux vs. low-flux haemodialysis: Effects on homocysteine and lipids
103. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients
104. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis
105. Labile methyl balances for normal humans on various dietary regimens
106. Withdrawal of folic acid supplementation in maintenance hemodialysis patients
107. Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism
108. Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients
109. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients
110. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients
111. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid
112. Cyclosporine use is not independently associated with increased plasma tHcy levels in Austrian or United States chronic renal transplant recipients
113. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: Effect of treatment with folic acid
114. The role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells
115. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients
116. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
117. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?
118. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?
119. Homocysteine: To screen and treat or to wait and see?